Prostate cancer accounts for 7.1% of new global cancers. Dr. Deep highlights that while PSA screening detects disease early, evidence warns of overdiagnosis and limited survival gains. Risk factors include age, BRCA mutations, and Black ethnicity. Individualised, evidence-based decisions on screening remain critical, balancing potential benefits against treatment-related morbidity.